Sanjeev has over 30 years of experience as a physician including over 14 years in the pharmaceutical/biotechnology industry. He has training and clinical practice experience in obstetrics-gynecology and internal medicine. Since joining the industry in 2000 at Lilly, he has been involved in drug development across several therapeutic areas and in all phases of clinical development. Sanjeev’s industry experience spans large pharmaceutical companies and start-ups. He helped establish the R&D joint venture for Lilly in India, managed the R&D collaborations in immunology-inflammation for Sanofi Genzyme, and till most recently was the Chief Medical Officer at On Target Laboratories. Sanjeev’s medical degree is from the Armed Forces Medical College, Pune, India. He is a Fellow of the American College of Physicians, and also has an MBA from the University of Cincinnati.
Dr. Springman joined Celtaxsys in 2009 from Locus Pharmaceuticals, where he held several positions of increasing responsibility including Head of Discovery and Technologies and Head of Development. At Locus, he was instrumental in building core technologies as well as discovering and developing 3 clinical candidate compounds resulting in over $50M in partnerships and $30M in venture funding. Additionally, Dr Springman obtained over $3M in public and private grant funding for research and served as an NIH SBIR grant reviewer. In 2007, Dr Springman was appointed by Gov. Edward Rendell to serve on the Pennsylvania Drug, Device and Cosmetics Board for which he served 4 years. Prior to Locus, Dr Springman served as Head of the Arthritis and Fibrosis Therapy Area at Roche Pharmaceuticals and Group Leader at Arris/Axys Pharmaceuticals. Dr Springman received his PhD in Molecular Biophysics from Florida State University and conducted his postdoctoral studies at Vanderbilt University School of Medicine, where he was an American Lung Association Fellow and NIH NRSA Postdoctoral Fellow. He was accepted into the American Academy of Allergy, Asthma and Immunology in 1993.
Angela Walsh joined the Celtaxsys team in March 2016 from Green Circle Bio Energy, a renewable energy company based in Cottondale, Florida. As the CFO of Green Circle, she was responsible for all aspects of strategic planning and financial reporting, audit and tax oversight, cash management, financial modeling and forecasting. Angela led the due diligence process for the acquisition of the Company by Enviva Partners, LP. Post the acquisition, Angela assisted Enviva in their preparations for their S-1 filing and subsequent IPO in May 2015. Before Green Circle, Angela worked five years for Altea Therapeutics, a start-up transdermal drug delivery company based in Atlanta, Georgia. In her role as the VP of Finance, she assisted in raising capital as well as assisted in the licensing of its technology to two pharmaceutical partners. Angela has over 25 years of experience in the accounting field and began her career with Arthur Andersen in Greensboro, North Carolina. Angela holds a B.S. in Accounting from Wake Forest University.
Previous experiences at Hoffman-La Roche Inc., Unilever, and Alteon Inc.
Previous experiences at GMP Companies, National Cardiovascular Network, and Emory University.
Previous experiences at Emory University, MCI WorldCom, Abbott Laboratories, and Henry M. Green & Associates.
Previous experiences at Upsher-Smith Laboratories, Vion Pharmaceuticals, Forest Laboratories, Purdue Pharma, and Carter-Wallace Labs.
Previous experiences at DOCS, Sebacia, ProTrials Research, Paragon Biomedical (now Clinipace Worldwide) and C&R Research Associates.
Previous experiences at Sanofi-Aventis, Cryolife, Molnlycke Healthcare and Covance.
Greg Duncan is the President and Chief Executive Officer of Celtaxsys, Inc. He was most recently Executive Vice President and President of North American Operations for Brussels based specialty pharma UCB. He was responsible for providing leadership and strategic direction to all aspects of the organization’s operations in North America. Prior to that, he was the President of European and Emerging Market Operations. Before joining UCB, Greg spent 17 years with Pfizer where he held several U.S. and international executive appointments, including SVP of Marketing and President of Pfizer’s Latin America Operations. His brand and general management teams had accountability for the launches of many “blockbuster” pharmaceutical brands including Lipitor, Zoloft, Viagra, Celebrex, Aricept, Lyrica, Cimzia, Zithromax (ZPack), Diflucan, Sutent and Vimpat.
Greg presently serves as an independent board director for Alliance Health and has served as a Board Director of the American Psychiatric Foundation, Biotie Therapeutics, Bio International Organization (BIO) and the Georgia Bio industry association groups. Greg holds a master’s degree in business administration from Emory University in Atlanta, GA, and a bachelor’s degree in economics from the State University of New York in Albany, NY. He and his wife Jennifer are the proud parents of three wonderful children.